Latest News

In an interview with Pharmacy Times, Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discussed how Inlexzo and increasingly complex urologic cancer therapies are driving closer coordination between urology and oncology pharmacy.

New ACC statement urges pharmacists to weigh cognition and frailty in every older adult's cardiovascular regimen.

Without an identifiable cure, pharmacists must prioritize prompt diagnosis and individualized symptom management.

The bill raises broader questions about pharmacist recognition as frontline care providers—not mere medication dispensers.

First-line trastuzumab deruxtecan significantly delayed disease progression in HER2-mutant advanced NSCLC.

Adding family-based behavioral treatment to standard care nearly doubled clinically meaningful weight loss in kids in the TEAM UP trial.

The all-oral combination of osimertinib and savolitinib significantly improved progression-free and overall survival following osimertinib resistance.

Topiramate, an antiseizure medication, has an off-label indication for cocaine use disorder and it received a conditional recommendation with a low certainty of evidence.

The agency's decision pairs a new self-administration device with label language tying LDL-C lowering to cardiovascular outcomes.

Every diagnosis comes with a workload for patients.

From patient selection to prior authorization: Tim Pflederer, MD, on delivering guideline-directed CKD care beyond the 15-minute visit.

Amid 2026 vaccine schedule changes, Trump executive order and vaccines spark confusion—see what’s legal, why AAP guides the childhood vaccine schedule.

The approval is supported by clinical data from 2 studies.

Pharmacists play a key role in translating COVID-19 variant surveillance data into patient-centered counseling on vaccine efficacy.

Prioritizing self-care is not optional; it is necessary for ongoing effectiveness and professional satisfaction.

Making cannabidiol water-soluble could reduce dissolution and food-related variability, but improved aqueous behavior has not yet been shown to produce better clinical outcomes.

The FDA's decision makes iberdomide the first approved CELMoD for patients with relapsed/refractory multiple myeloma.

This study strengthens the evidence base supporting current guidelines and may help reverse the recent decline in pediatric antiviral use.

Active surveillance increased from 27% in 2005 to 93% in 2024, reflecting a major shift away from immediate treatment for favorable-risk disease.

Modeling in Canada suggests price drops of up to 70% could make dual glucagon-like peptide-1 (GLP-1) RA/SGLT2 inhibitor therapy the preferred strategy for high-risk patients with type 2 diabetes (T2D).

When a PA is incomplete or missing the right documentation, the rejection lands at the pharmacy counter, not the prescriber's desk.